Advanced

Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers

Handels, Ron L H; Vos, Stephanie J B; Kramberger, Milica G.; Jelic, Vesna; Blennow, Kaj LU ; van Buchem, Mark; van der Flier, Wiesje; Freund-Levi, Yvonne; Hampel, Harald and Olde Rikkert, Marcel, et al. (2017) In Alzheimer's and Dementia 13(8). p.903-912
Abstract

Introduction: We aimed to determine the added value of cerebrospinal fluid (CSF) to clinical and imaging tests to predict progression from mild cognitive impairment (MCI) to any type of dementia. Methods: The risk of progression to dementia was estimated using two logistic regression models based on 250 MCI participants: the first included standard clinical measures (demographic, clinical, and imaging test information) without CSF biomarkers, and the second included standard clinical measures with CSF biomarkers. Results: Adding CSF improved predictive accuracy with 0.11 (scale from 0-1). Of all participants, 136 (54%) had a change in risk score of 0.10 or higher (which was considered clinically relevant), of whom in 101, it was in... (More)

Introduction: We aimed to determine the added value of cerebrospinal fluid (CSF) to clinical and imaging tests to predict progression from mild cognitive impairment (MCI) to any type of dementia. Methods: The risk of progression to dementia was estimated using two logistic regression models based on 250 MCI participants: the first included standard clinical measures (demographic, clinical, and imaging test information) without CSF biomarkers, and the second included standard clinical measures with CSF biomarkers. Results: Adding CSF improved predictive accuracy with 0.11 (scale from 0-1). Of all participants, 136 (54%) had a change in risk score of 0.10 or higher (which was considered clinically relevant), of whom in 101, it was in agreement with their dementia status at follow-up. Discussion: An individual person's risk of progression from MCI to dementia can be improved by relying on CSF biomarkers in addition to recommended clinical and imaging tests for usual care.

(Less)
Please use this url to cite or link to this publication:
@article{da6d3815-0089-44aa-b3c4-e7813f27b838,
  abstract     = {<p>Introduction: We aimed to determine the added value of cerebrospinal fluid (CSF) to clinical and imaging tests to predict progression from mild cognitive impairment (MCI) to any type of dementia. Methods: The risk of progression to dementia was estimated using two logistic regression models based on 250 MCI participants: the first included standard clinical measures (demographic, clinical, and imaging test information) without CSF biomarkers, and the second included standard clinical measures with CSF biomarkers. Results: Adding CSF improved predictive accuracy with 0.11 (scale from 0-1). Of all participants, 136 (54%) had a change in risk score of 0.10 or higher (which was considered clinically relevant), of whom in 101, it was in agreement with their dementia status at follow-up. Discussion: An individual person's risk of progression from MCI to dementia can be improved by relying on CSF biomarkers in addition to recommended clinical and imaging tests for usual care.</p>},
  author       = {Handels, Ron L H and Vos, Stephanie J B and Kramberger, Milica G. and Jelic, Vesna and Blennow, Kaj and van Buchem, Mark and van der Flier, Wiesje and Freund-Levi, Yvonne and Hampel, Harald and Olde Rikkert, Marcel and Oleksik, Ania and Pirtosek, Zvezdan and Scheltens, Philip and Soininen, Hilkka and Teunissen, Charlotte and Tsolaki, Magda and Wallin, Asa K. and Winblad, Bengt and Verhey, Frans R. J. and Visser, Pieter Jelle},
  issn         = {1552-5260},
  keyword      = {Alzheimer's disease,Conversion,Dementia,Mild cognitive impairment,Predict,Prognosis,Progression,Reclassification,Risk,Risk prediction model},
  language     = {eng},
  number       = {8},
  pages        = {903--912},
  publisher    = {Elsevier},
  series       = {Alzheimer's and Dementia},
  title        = {Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers},
  url          = {http://dx.doi.org/10.1016/j.jalz.2016.12.015},
  volume       = {13},
  year         = {2017},
}